The relationship of Lysophosphatidylcholine level with mortality in Covid Pneumonia

INTRODUCTION: The aim of this study was to investigate the relationship between serum Lysophosphatidylcholine (LPC) levels and mortality in patients diagnosed with Covid-19 admitted to the emergency department and hospitalised.METHODS: The study was designed as a prospective, cross-sectional study. The effect of serum LPC levels taken on days 1 and 5 on prognosis in patients diagnosed with Covid 19 in the emergency department was investigated.RESULTS: The average age of the patients included in our study was 73.9, with males constituting 56.8%. The most common comorbidities were hypertension (72.7%) and diabetes mellitus (43.2%). The most common presenting symptoms were fatigue and widespread body pain, cough, and dyspnoea, consistent with the cardinal symptoms of the disease. After the emergency department visit, 77.3% of the patients were hospitalized, while 22.7% were admitted to the intensive care unit. 79.5% were discharged, while 20.5% died. In the group with fatal outcomes, the day 1 LPC level was significantly lower (p < 0.05) compared to the discharged group. A significant [Area under the curve (AUC): 0.830; Confidence Interval (CI): 0.683-0.977)] effectiveness of the 10000-cut-off value of LPC on the 1st day was observed in distinguishing between patients discharged and deceased. The sensitivity was 88.9%, positive predictive value 50.0%, specificity 77.1%, and negative predictive value 96.4%.DISCUSSION AND CONCLUSION: We found that the day 1 LPC level may be a valuable biomarker for prognosis in patients presenting to the emergency department with Covid pneumonia due to its high sensitivity, moderate specificity, and advanced negative predictive value for mortality.